The Chemotherapy Foundation

Home
United States
New York, NY
The Chemotherapy Foundation

The Chemotherapy Foundation is dedicated to advancing innovative cancer research at all New York City medical institutions.

We are unique both in our approach and focus.

07/30/2026

What we call “ovarian cancer” may often begin somewhere else. Research increasingly shows that many ovarian cancers, particularly high-grade serous cancers, originate in the fallopian tubes. This evolving understanding is changing how researchers and clinicians think about prevention.

It’s a powerful reminder of why cancer research matters. For more than 55 years, TCF has supported emerging oncology talent and innovative research that challenges assumptions and moves promising ideas closer to patient impact.

Science moves forward when we invest in discovery. 🔬💙

Read the full article from The New York Times:
https://www.nytimes.com/2026/07/28/health/ovarian-cancer-fallopian-tubes.html?unlocked_article_code=1.1FA.YOWU.FuPrXE7wVvOG&smid=nytcore-ios-share

07/28/2026

In the latest episode of We Speak Cancer, we sit down with one of the field’s leading experts and ask “What are the biggest changes in treatment and patient care that you’ve seen over the last decade?”

Hosted by Paola G. Muggia, our Executive Director, this episode features Stephanie Blank, valued member of our Medical Advisory Council and Director of Gynecologic Oncology for the Mount Sinai Health System and Associate Director for Women’s Cancers at the Tisch Cancer Institute.

Together, they discuss the latest advances in gynecologic oncology and the evolving landscape of cancer prevention, diagnosis, and treatment.

Full Episode linked in our bio!

07/16/2026

Last week, The Chemotherapy+ Foundation welcomed physicians, researchers, patients, and friends for an inspiring evening in the Hamptons dedicated to connection, collaboration, and the future of cancer care. Pictured is Che-Kai Tsao, MD, André Goy, MD, Joseph Sparano, MD, FACP, Michael Rosenberg, TCF Chair, Dr. Rob Winn, Cora Sternberg, MD, Silvia Formenti, MD, John Leonard, MD, and William Oh, MD, TCF MAC Chair.

For nearly 60 years, The Chemotherapy+ Foundation has been a leader in advancing cancer research by investing in innovative ideas and the next generation of physician-scientists. Our Hamptons gathering offered guests a unique opportunity to learn more about our mission, engage with leaders in oncology, and discover how collaboration between researchers, clinicians, patients, and advocates is transforming the future of cancer care.

More than a summer gathering, the evening was an opportunity to introduce new friends to the Foundation and expand our community of supporters who believe that meaningful medical progress is only possible when we work together!

We extend our heartfelt gratitude to Michael G. Rosenberg, Chair of The Chemotherapy+ Foundation, for graciously hosting this special evening in the Hamptons.

A special thank you to Michael Longoria from Jersey Boys, James Obiak, and Garrison Mack for an unforgettable performance. Their extraordinary talent helped create a memorable experience for our guests and perfectly captured the spirit of community that defines The Chemotherapy+ Foundation.

We are incredibly grateful to our generous in-kind sponsors, whose support helped give the event a special touch! With sincere appreciation to PIM Brands, Solubrae, Summer Club, Koala Eco, Create Wellness, MASA Chips, VIO2, 4AM, Bloom Nutrition, and SunSingles.

07/07/2026

A metastatic breast cancer diagnosis often raises questions beyond treatment, including how everyday lifestyle choices like drinking alcohol may affect your health.

Alcohol is a known risk factor for breast cancer and may also interfere with certain cancer therapies, increase fatigue and dehydration, worsen treatment-related side effects, and place additional stress on the liver. While every patient's care plan is unique, many experts recommend limiting or avoiding alcohol during cancer treatment.

Making informed lifestyle choices and maintaining open communication with your healthcare team are important parts of supporting your overall health during treatment!

06/29/2026

Breakthroughs in cancer care happen because researchers continue to ask bold questions.

New results from the Phase III PROTEUS trial suggest that adding apalutamide to standard therapy before and after surgery may significantly improve outcomes for patients with high-risk localized prostate cancer. The findings are being viewed as a potential shift in the treatment landscape.

As Chairman of TCF's Medical Advisory Committee, Dr. William Oh has long been a leader in advancing prostate cancer research and bringing promising innovations closer to patients.

At TCF, we're proud to support the oncology ecosystem that drives discoveries like these forward!

06/23/2026

How are advances in screening, genetic testing, and targeted therapies changing the future of gynecologic cancer care? In the latest episode of We Speak Cancer, we sit down with one of the field’s leading experts to find out.

Hosted by Paola G. Muggia, our Executive Director, this episode features Stephanie Blank, valued member of our Medical Advisory Council and Director of Gynecologic Oncology for the Mount Sinai Health System and Associate Director for Women’s Cancers at the Tisch Cancer Institute.

Together, they discuss the latest advances in gynecologic oncology and the evolving landscape of cancer prevention, diagnosis, and treatment, including:
• Recommended screening and risk assessment strategies for women and individuals with a family history of gynecologic cancers
• The growing role of genetic testing in guiding treatment decisions
• Challenges in detecting gynecologic cancers at earlier stages
• Emerging therapies and promising developments in ovarian cancer treatment
• The science and potential of Antibody-Drug Conjugates (ADCs)
• Innovations that may shape the future of gynecologic oncology over the next decade

Through expert-led conversations like these, We Speak Cancer continues to make cancer research and treatment advances more accessible to patients, caregivers, advocates, and the broader community.

Full Episode linked in our bio!

06/15/2026

The 2026 ASCO Annual Meeting showcased remarkable advances in cancer research. From promising pancreatic cancer therapies to smarter immunotherapy approaches and increasingly personalized treatment strategies.

One message was clear: today's breakthroughs are the result of years of dedication, collaboration, and investment in scientific innovation.

At TCF, we believe in supporting emerging oncology talent and transformative research that advances prevention, treatment, and survivorship!

06/08/2026

Today, on , we stand with the more than 1.3 million Americans living with a primary brain tumor and honor the strength of every patient, survivor, caregiver, and healthcare professional affected by this disease.

Brain tumors remain one of the most challenging cancers to diagnose and treat. This year alone, an estimated 108,810 Americans will receive a primary brain tumor diagnosis, and 18,350 lives will be lost to malignant brain tumors.

At TCF, we believe that progress begins with innovation. By supporting emerging oncology researchers and advancing groundbreaking cancer research, we help create new possibilities for better treatments, improved outcomes, and hope for patients everywhere.

Together, we can accelerate discoveries that change lives!

06/04/2026

What will the future of oncology look like? According to Dr. Larry Norton, a member of our Medical Advisory Council and one of cancer research's most respected voices, progress depends on our willingness to challenge assumptions, embrace new technologies, and work together across borders.

In this recent article, he discusses three powerful ideas shaping the next era of cancer care:
🔬 Questioning entrenched concepts can lead to breakthrough discoveries.
🤖 Artificial intelligence has the potential to transform cancer research and personalize treatment like never before.
🌎 The challenges of cancer are universal—and so must be the solutions.

As Dr. Norton reminds us, "Would any patient dying of cancer in one country reject a cure just because it was discovered in another?"

At The Chemotherapy+ Foundation, we believe advancing cancer care starts with supporting innovative researchers, fostering collaboration, and investing in the ideas that have the potential to change lives.

Together, we can help accelerate the breakthroughs of tomorrow.

06/01/2026

June marks ! We celebrate the strength, resilience, and courage of the millions of survivors who inspire us every day.

Today, nearly 18.6 million Americans are living as cancer survivors—a number projected to grow to more than 22 million by 2035. Every survivor represents a story of perseverance, hope, and the power of innovation in cancer care.

At The Chemotherapy+ Foundation, we remain committed to funding the next generation of oncology leaders and research breakthroughs that help create more survivor stories.

Join us in honoring survivors, caregivers, clinicians, and researchers who make progress possible!

Address

New York, NY

Telephone

+12122139292

Website

https://www.chemotherapyfoundation.org/

Alerts

Be the first to know and let us send you an email when The Chemotherapy Foundation posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Organization

Send a message to The Chemotherapy Foundation:

Featured

Heart River Center for Intuitive Healing

Want your organization to be the top-listed Non Profit Organization in New York?